Baseline characteristics

A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM) · Source last updated 2022-01-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

1. counts

   1. group Id

      BG000

      value

      0

   units

   Participants

groups

1. description

   3 patients recruited into the study but no patients received Temferon. Study terminated due to inability to recruit additional patients in view of the ongoing COVID-19 pandemic

   id

   BG000

   title

   Patient Recruitment

measures

1. classes

   1. categories

      1. title

         <=18 years

      2. title

         Between 18 and 65 years

      3. title

         >=65 years

   title

   Age, Categorical

2. title

   Age, Continuous

3. classes

   1. categories

      1. title

         Female

      2. title

         Male

   title

   Sex: Female, Male

4. classes

   1. categories

      1. title

         American Indian or Alaska Native

      2. title

         Asian

      3. title

         Native Hawaiian or Other Pacific Islander

      4. title

         Black or African American

      5. title

         White

      6. title

         More than one race

      7. title

         Unknown or Not Reported

   title

   Race (NIH/OMB)

5. title

   Race/Ethnicity, Customized

6. classes

   1. title

      Italy

   title

   Region of Enrollment

   unit Of Measure

   participants

population Description

No patients completed the baseline visit

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice